| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 13,590 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -54,810 | -36,840 | -28,030 | -32,210 | -33,000 |
| Net Income Growth | -48.78% | -31.43% | +12.98% | +2.39% | -12.09% |
SC Pharmaceuticals Inc (SCPH)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
3.00 -0.01 (-0.33%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.99 -0.01 (-0.33%) 19:45 ET
for Fri, Mar 21st, 2025
scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company's pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States.
Fiscal Year End Date: 12/31